The US Food and Drug Administration (FDA) has approved Abbott’s drug eluting stent system, which is designed to improve coronary artery luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions.

The Xience Xpedition Everolimus Eluting Coronary Stent system, which will be available in rapid exchange (RX) and over-the-wire (OTW) configurations, has proven to be safe for direct stenting, which does not require another device such as a balloon dilatation catheter to prepare the lesion.

Featuring a new stent delivery system, the system has diameter ranging from 2.25mm to 4mm, including a unique 3.25mm diameter, and lengths from 8mm to 38mm, for more accurate vessel sizing.

The approval is supported by robust clinical evidence from the Xience family of drug eluting stents, including data from more than 45,000 patients across more than 100 studies, with long-term outcomes out to five years.

Data has consistently shown an excellent safety profile for the Xience family of stents, according to the company.

Abbott medical devices executive vice president John Capek said; “Xience Xpedition leverages the strong clinical outcomes of Xience V and Xience Prime while providing important advantages in deliverability.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mount Sinai Medical Center Clinical and Interventional Cardiology director, International Clinical Affiliations dean and Mount Sinai Heart Network president Dr Samin Sharma said; “Xience Xpedition represents a powerful combination of deliverability, strong clinical data and broad availability of meaningful sizes – three factors that make this product well-suited to treat a wide range of patients.”